NCT02678260View on ClinicalTrials.gov

Phase I Study of PDR001 in Patients With Advanced Malignancies.

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

September 1, 2017

Study Completion Date

September 1, 2017

Conditions
Advanced Malignancies
Interventions
DRUG

PDR001

PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.

Trial Locations (3)

466-8560

Novartis Investigative Site, Nagoya

277-8577

Novartis Investigative Site, Kashiwa

650-0017

Novartis Investigative Site, Kobe

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY